Intravitreal Bevacizumab Treatment for Choroidal Neovascularization in Pathologic Myopia: 12-month Results
- 9 September 2008
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 147 (1), 84-93.e1
- https://doi.org/10.1016/j.ajo.2008.07.022
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot studyBritish Journal of Ophthalmology, 2007
- Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopiaBritish Journal of Ophthalmology, 2007
- Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopiaBritish Journal of Ophthalmology, 2007
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- SAFETY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN RABBIT EYESRetina, 2006
- TREATMENT OF CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA WITH INTRAVITREAL BEVACIZUMABRetina, 2006
- Effects of bevacizumab on retinal function in isolated vertebrate retinaBritish Journal of Ophthalmology, 2006
- Errors in Retinal Thickness Measurements Obtained by Optical Coherence TomographyOphthalmology, 2006
- Bevacizumab suppresses choroidal neovascularisation caused by pathological myopiaBritish Journal of Ophthalmology, 2005